Inhibition of *Plasmodium yoelii* blood-stage malaria by interferon \(\alpha\) through the inhibition of the production of its target cell, the reticulocyte

Ana Margarida Vigário, Elodie Belnoue, Ana Cumano, Myriam Marussig, François Milgten, Irene Landau, Dominique Mazier, Ion Gresser, and Laurent Rénia

The effect of a recombinant hybrid human interferon \(\alpha\) (IFN\(\alpha\)) (which cross-reacts with murine cells) on C57BL/6 mice infected with *Plasmodium yoelii* sporozoites or parasitized erythrocytes was determined. IFN\(\alpha\) did not inhibit the development of the parasite in the liver, but it did reduce the blood parasite load and the hepatosplenomegaly induced by the infection in mice injected with blood-stage parasites. The extent of anemia in IFN\(\alpha\)-treated and control mice was similar, despite the lower parasite load in the IFN\(\alpha\)-treated mice.

The reduced blood parasite load in IFN\(\alpha\)-treated mice was associated with reduced erythropoiesis and reticulocytosis. As reticulocytes are the preferred target cells for the strain of *P. yoelii* used (*P. yoelii* yoelii 265 BY), it was postulated that the inhibition of reticulocytosis in IFN\(\alpha\)-treated mice was causally related to the observed decreased blood parasite load. This was supported by the finding that IFN\(\alpha\) inhibited a different strain of *P. yoelii* (17X clone A), which also displays a tropism for reticulocytes, but not a line of *Plasmodium vinckei petteri*, which infects only mature red blood cells. As human malaria species also display different tropism for reticulocytes, these findings could be relevant for people coinfected with multiple *Plasmodium* species or strains or coinfected with *Plasmodium* and virus. (Blood. 2001;97: 3966-3971)

© 2001 by The American Society of Hematology

Introduction

Malaria remains a disease that is estimated to kill 1.5 million to 2.7 million people each year. The parasite and its mosquito vector have become resistant to several drugs in recent years, and this has stimulated a search for new therapeutic strategies. Recombinant cytokines can confer protection against bacterial, viral, and some intracellular parasitic infection. Some of these cytokines can also inhibit the development of the malaria parasite. Recombinant interferon \(\gamma\) (IFN\(\gamma\)) inhibits the development of the liver stage of murine, simian, and human malaria in vitro and in vivo. Protection against murine and simian malaria is also obtained after treatment with recombinant (r) IL-12. 5-7

Type I interferons were originally described as potent antiviral substances that are produced by animal cells infected with virus. However, the role of type I IFNs in the defense against nonvirus pathogen is much less well studied. 8 IFN type I (IFN-\(\alpha\) or \(\beta\)) inducers, such as Newcastle disease virus, staphyloc, or polyribosinopri-bicytidylic acid, 9,13 and unpurified serum IFN 14 protect against *Plasmodium berghei* infection. However, the action of IFN-\(\alpha\) alone is still not known.

In this study, we have analyzed the effect of a recombinant human IFN\(\alpha\)-hybrid that cross-reacts with murine cells on the course and the pathology of infection with different species or strains of rodent *Plasmodium*, initiated by inoculation with either sporozoites or parasitized erythrocytes. We show that inhibition of parasite-induced reticulocytemia by IFN\(\alpha\) influences only parasite species that are restricted to reticulocytes. Our results extend previous observations whose interpretation is complicated by the fact that a corticosteroid, which is a potent immunosuppressor, was used to alter reticulocyte production. We discuss our results in the context of the role of cytokines in the pathogenesis of malaria.

Materials and methods

Mice and parasites

Female C57BL/6 mice, 5 to 6 weeks old, were purchased from Charles River Breeding Laboratories (Saint Aubin-les-Elbeuf, France). Sporozoites of the uncloned line of the 265 BY strain of *Plasmodium yoelii yoelii* were obtained from infected salivary glands of *Anopheles stephensi* mosquitoes, 16 to 21 days after a meal of blood from an infected mouse. The salivary glands were dissected out aseptically, homogenized in an all-glass grinder, and diluted in culture medium or phosphate-buffered saline (PBS). Sporozoites were counted, and mice were injected intravenously (IV) with 4000 or 20,000 sporozoites. The blood parasites used in this study were from the uncloned line (265 BY) or from a cloned line, clone A, of the 17X NL strain 16,17 (kindly given by Dr G. Snounou, Imperial School of Medicine, London, England) of the *P. yoelii* yoelii strain. Blood parasites of an uncloned line of *Plasmodium vinckei petteri* 106HW were also used. The parasites were suspended in Alsever's buffer and stored as a frozen stablate in liquid nitrogen. Mice were inoculated intraperitoneally (IP) with 10\(^7\) parasitized erythrocytes (PEs) in 100 \(\mu\)L Alsever buffer.

From INSERM Unité 445, ICGM, Université René Descartes, Hôpital Cochin; Unité du Développement des Lymphocytes, Institut Pasteur; INSERM Unité 511, Hôpital Pitéé-Salpétrière; and Muséum National d’Histoire Naturelle, Paris, France; and Laboratoire d’Oncologie Virale (UPR 9045), Institut de Recherches sur le Cancer, Villejuif, France.

Submitted November 30, 2000; accepted February 13, 2001.

Supported by a grant from the Institut Electrique et Santé (L.R.) and a fellowship (BM1455/94 and BD9255/96 to A.M.V.) from the Junta Nacional de Investigação Científica e Tecnológica, Portugal.

Reprints: Laurent Renia, INSERM U445, ICGM, Hôpital Cochin, Bâtiment Gustave Roussy, 27, rue du Fbg Saint Jacques, 75014 Paris, France; e-mail: renia@icgm.cochin.insERM.fr.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.
**IFN-α treatment**

A recombinant hybrid IFN-α (BDBB, a hybrid of α8 and α1, CIBA-GEIGY 35269) was a gift from Dr Marcus Grueter (Ciba Geigy, Basel, Switzerland). Its specific activity on mouse embryonic fibroblasts was 5.1 x 10^5 U/mg.18 The lyophilized IFN-α was suspended in PBS containing 0.1% (wt/vol) bovine serum albumin (BSA) (fraction V) (Sigma Chemical, St Louis, MO). The control was 0.1% BSA in PBS. Liver-stage studies were done in mice treated daily with IFN-α or the control preparation for 4 days, starting the day before the IV injection of sporozoites. Blood-stage studies were done in mice that were first injected IP with 200 μL IFN-α (5 x 10^4 units [U] per injection) or the control preparation and then injected IP with the parasites 1 hour later. Treatment was continued daily for 25 days.

**Quantification of *P. yoelii* ribosomal DNA in the liver of infected mice**

Quantification was performed as described.19 Liver biopsies (100 mg, corresponding to one fourth of the right lobe) were removed 42 hours after injection of 20,000 sporozoites, frozen in liquid nitrogen, and stored at −80°C for subsequent DNA isolation. Genomic DNA was extracted by means of the Easy-DNA kit (Invitrogen, San Diego, CA). DNA pellets were air-dried for 5 minutes at room temperature and suspended in 100 μL TE (10 mM Tris-HCl; 1 mM EDTA, pH 8.0; 5% sarcosyl; 200 μg/mL proteinase K) at 37°C for 30 minutes. They were then stored at 4°C before being used as a template in a polymerase chain reaction (PCR) using the following malaria oligonucleotide primers: rPLU3 5'-TTT TAA TAG TAA CTA CGG AAA AGC TGT-3' and rPLU4 5'-TAC CGG AAA AGC TGT-3'. Template DNA (1 μg DNA sample) was added to a solution containing (final concentrations) 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 0.01% gelatin, 1% Triton X-100, 200 μM deoxynucleoside triphosphate, 125 nM of each primer, and 0.5 U Taq polymerase (ATGC Biotechnologie, Noisy le Grand, France) in a total volume of 50 μL. The solution was subjected to 45 cycles of amplification with an OmniGene Temperature Cycler (Hybaid, Teddington, England). In each cycle of PCR, the mixture was denatured at 95°C for 45 seconds (5 minutes for the first cycle), annealed at 64°C for 45 seconds, and extended at 72°C for 1 minute. The quality and quantity of the DNA extraction were assessed before amplifying the β2-microglobulin gene for all samples by means of the following primers: 5'-GGC TCG CTC CGT GAC CCT AGT AGT CTT T-3' and 5'-TCT GCA GGC GTA TGT ATC AGT CTC A-3'. The conditions of amplification were 60°C for 20 seconds for annealing. PCR products (243 base pairs [bp] for ribosomal DNA or 300 bp for β2-microglobulin) were visualized by gel-electrophoresis and ethidium bromide staining. Plasmoid PMC products were quantitated by high-pressure liquid chromatography. Briefly, 20 μL PCR reaction was passed through an ion exchange column (Gen-Pack FAX column) (Waters, Milford, MA) to separate the PCR product from the other components of the PCR reaction. The elution peak of the amplified fragment was identified, and its elution peak of the amplified fragment was identified, and its elution peak of the amplified fragment was identified, and its elution peak of the amplified fragment was identified, and its elution peak of the amplified fragment was identified, and its elution peak of the amplified fragment was identified. 18

**Results**

**Effect of IFN-α on the *P. yoelii* 265 BY liver stage**

Daily injections of IFN-α (5 x 10^4 U) for 4 days, starting on the day before the mice were inoculated with 4000 sporozoites, did not prevent the development of parasitemia (Table 1, experiment 1). Moreover, IFN-α–treated mice developed parasitemia at the same time as the control mice, and the time courses of parasitemia in the 2 groups were similar (data not shown). These results were
confirmed by determining the parasite load in the liver by quantitative PCR. Mice challenged with 20,000 sporozoites and treated with IFN-α as in experiment 1 had amounts of parasite ribosomal DNA in their livers similar to the control mice 42 hours after challenge (Table 1, experiment 2). Thus, IFN-α did not inhibit the liver stage of malaria.

**Effect of IFN-α on blood parasite development**

C57BL/6 mice injected with the blood stage of the uncloned line of *P. yoelii* 265 BY normally develop a moderate blood parasite load, and most of the mice recover from the infection (Figure 1), although mortality can occur when parasitemia and anemia develop rapidly. The parasitemia was significantly lower in mice treated with IFN-α than in controls, and parasites were cleared sooner from the blood of treated mice than in controls (Figure 1A). This effect on parasite development was also seen when blood parasite load was evaluated (Figure 1B).

**Influence of IFN-α on hepatosplenomegaly in infected mice**

Infection with *Plasmodium* species causes marked hepatosplenomegalgy. As IFN-α inhibited the development of blood parasites, we determined the effect of IFN-α on the liver and spleen weights of mice infected with *P. yoelii* 265 at 6, 14, and 30 days after inoculation of the parasite. The splenomegaly in IFN-α-treated mice was significantly less pronounced than in controls (P < .05) on day 14 (Table 2). This difference was no longer observed 30 days after infection (data not shown). But the malaria-associated splenomegaly in IFN-α-treated mice was significantly less pronounced than in controls (P < .05) hepatomegaly on day 14 (Table 2).

Autopsies of the livers and spleens of IFN-α–treated parasite-injected mice revealed that they were lighter colored than those of control mice, indicating less parasite pigment in these organs. This was confirmed histologically (data not shown).

**Effect of IFN-α on malaria-induced anemia**

Despite the reduction of blood parasite load by IFN-α, the severity of anemia (measured by Hb level and RBC count) was the same in IFN-α–treated and control mice (Figure 2). Both groups of mice were markedly anemic after infection with *P. yoelii* 265 BY, with the lowest Hb concentrations and RBC counts on days 12 to 22. There were slight decreases in Hb and RBC counts in IFN-α–treated uninfected mice (data not shown).

**Dox clip begin**

| Table 1. Influence of interferon-α on the *P. yoelii* liver stage in vivo |
|---------------------------------|-----------------|-----------------|
| **Treatment**                  | Infected mice/challenged mice (experiment 1) | *P. yoelii* ribosomal DNA in the liver (log pg)† |
| Control preparation            | 5/5             | 0.88 ± 0.13     |
| Interferon α                   | 5/5             | 0.68 ± 0.13     |

NS indicates not significant (P = .26).

* Mice were given 5 × 10⁸ U interferon-α or control preparation daily for 4 days beginning the day before challenge.† Mice were challenged intravenously with 4000 sporozoites. Mice were considered infected when they developed parasitemia.

**Erythropoiesis during IFN-α treatment of malaria infection**

As the level of parasitemia is usually directly correlated with the degree of malaria-induced anemia,26 we undertook experiments to understand the dissociation between them in IFN-α–treated mice (ie, reduced blood parasite load with no reduction in the extent of anemia).

The numbers of early (BFU-E) and late erythroid (CFU-E) progenitors in the bone marrow and spleen were measured on day 14, a few days before the peak of reticulocytosis, in mice injected with *P. yoelii* 265 BY inoculated intravenously with 4000 sporozoites.

| Table 2. Effect of interferon-α on hepatosplenomegaly and parasitemia |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
| **Treatment**                  | BSA IFN-α       | BSA + IFN-α     | IFN-α + IFN-α   | BSA + IFN-α     |
| Liver weight, mg               | 1010 ± 61       | 802 ± 50        | 1340 ± 25       | 1092 ± 25†      |
| Spleen weight, mg              | 93 ± 4          | 94 ± 11         | 686 ± 50        | 389 ± 16†       |
| Parasitemia, %                 | —               | 16.4 ± 9.8      | 0.8 ± 0.5†      |

BSA indicates bovine serum albumin; IFN, interferon; *P. yoelii*, Plasmodium yoelii.‡ Mice, infected or uninfected, were injected daily with 0.1% BSA or recombinant human IFN-α. Samples were taken 14 days after *P. yoelii* 265 BY inoculation. Results are mean ± SE of 4 mice per group. The experiment was repeated twice with similar results.

†Significantly different (P < .05). P values were calculated by comparing IFN-α–treated infected mice with the corresponding infected control mice (Mann-Whitney test).
with *P. yoelii* 265 BY. The number of BFU-E in the bone marrow was slightly decreased in control infected mice (Figure 3A), whereas the number of CFU-E was significantly increased (Figure 3C). This increase in CFU-E was not so great in IFN-α–treated mice (Figure 3C).

There was a slight increase in the BFU-E in the spleens of infected and IFN-α–treated animals (Figure 3B). As in the bone marrow, there was a marked increase in total spleen CFU-E in infected untreated mice. This increase was less marked in IFN-α–treated infected mice (Figure 3D).

**Effect of IFN-α on reticulocytosis induced by malaria infection**

The infection of mice with *P. yoelii* causes them to become anemic, which then results in reticulocytosis. The number of reticulocytes in the blood of IFN-α–treated and control infected mice remained within the normal range, less than 5%, until day 8 (Figure 4). The number of reticulocytes then increased in both groups, but reticulocytosis was less marked (*P < .05 on days 10 to 18) in mice treated with IFN-α (Figure 4) (the percentage of reticulocytes in uninfected mice remained under 8%). Most (60% to 100%) of the parasitized cells were reticulocytes, demonstrating the selective tropism of the *P. yoelii* strain 265 BY for reticulocytes. This was not changed by IFN-α treatment (data not shown).

**Effect of IFN-α on blood parasite loads of other strains or species of rodent *Plasmodium***

Different strains of *Plasmodium* have different tropism for mature and immature RBCs. As the effect of IFN-α on parasitemia was associated with the reduction in circulating reticulocytes in a *Plasmodium* strain with a tropism for reticulocytes, we assessed the effect of the same treatment on other strains or species that had different tropism for RBCs. We used 2 different parasites. One was a cloned line from the *P. yoelii* 17X isolate that also preferentially infects reticulocytes (Fahey and Spitalny21 and our observations) and causes a moderate parasitemia in C57BL/6 mice (*P. yoelii* 17X NL, clone A). The other species used (*P. vinckei petteri* 106HW) causes a fulminate infection and shows a tropism for mature cells (our observation).

As for *P. yoelii* 265 BY infected mice, IFN-α also reduced the blood parasite load of mice infected with *P. yoelii* clone A during the first peak of infection, but not during recrudescence, which occurs when IFN-α treatment was stopped (Figure 5). However, IFN-α had no effect on the development of the blood parasite load of mice infected with *P. vinckei*: all the mice, both treated and untreated, died 9 to 11 days after infection (Figure 5). Almost
We have shown that treatment with recombinant hybrid human IFN-α (BDBB), which is biologically active on murine cells, reduced blood parasite load in mice infected with parasitized erythrocytes of 2 different parasites with a specific tropism for reticulocytes (P yoelii 265 BY or P yoelii 17X NL clone A), but not in mice infected with a line with tropism for mature RBCs (P vinckei petteri). The reduction in the blood parasite load of IFN-α–treated mice was also accompanied by a less severe hepatosplenomegaly (especially on day 14 after infection).

However, IFN-α did not inhibit the liver-stage infection with P yoelii 265 BY sporozoites (Table 1). These results do not agree with published reports that indicate type I IFN or a crude serum IFN strongly suppressed the infection of mice with P berghei sporozoites. Aside from the fact that we used P yoelii rather than P berghei, the major reason may be that we used a pure recombinant IFN-α, whereas previous investigators used IFN inducers, which can induce the production of IFN-α, IFN-β, and even some IFN-γ, as well as other cytokines such as IL-6, which can inhibit liver-stage malaria both in vivo and in culture.

It is difficult to understand how IFN-α inhibits blood-stage malaria. Schultz et al. reported that P berghei–parasitized erythrocytes were much less infective or not infective after incubation with crude serum containing IFN. Many years ago, we were unable to confirm these results when we used partially purified cell-culture IFN-α/β (I.G., unpublished observations, 1970), and information obtained during the past 30 years on how IFN acts indicates that IFN is unlikely to act on cells without nuclei (ie, erythrocytes). If IFN-α does not act directly on parasitized cells, it must act in some other manner in malaria-infected animals. C57/BL/6 mice infected with P yoelii rapidly became severely anemic. Our examination of the erthropoietic response to malaria infection in untreated mice infected with parasitized erythrocytes showed an increase in CFU-E colonies in the bone marrow and spleen of mice 14 days after infection with P yoelii 265 BY. This increase was inhibited in IFN-α–treated mice. Likewise, more than 60% reticulocytes were observed in malaria-infected control mice, at the peak of infection, whereas the percentage of reticulocytes was much lower (approximately 30%) in IFN-α–treated mice. The reticulocytes were the cellular target for this strain of P yoelii, in both control and IFN-α–treated mice, as 60% to 100% of the parasitized cells were reticulocytes at the peak of parasitemia.

We suggest that the reduction in the blood parasite load in IFN-α–treated mice is due to the fewer reticulocytes available for infection by P yoelii and that the decreased number of reticulocytes is due to the inhibition by IFN-α of splenic CFU-E in infected mice. This was confirmed in experiments showing that IFN-α inhibits P yoelii 17X clone A, which also infects reticulocytes, but not P vinckei petteri, which infects only mature RBCs. It has to be noted that β-methasone, a drug that suppresses erythropoiesis, also selectively inhibits an uncloned line of P yoelii 17X, which infects reticulocytes, but not P vinckei chabaudi, which does not.

The degree of anemia in malaria is usually correlated with the blood parasite load, especially with rodent malaria parasites. It was surprising, therefore, to find that the onset and degree of anemia in mice infected with P yoelii 265 BY was the same in both control and IFN-treated mice, despite the reduced blood parasite load. As there was a reduced blood parasite load in IFN-α–treated mice, there was also less lysis of RBCs in these mice. But there were fewer CFU-E in IFN-α–treated mice, which resulted in fewer reticulocytes, and thus it may have contributed to the profound anemia in these mice. IFN-α may have inhibited erythropoiesis directly or indirectly by inducing the production of other molecules that can inhibit erythropoiesis, such as nitric oxide or IFN-γ.

Despite the extent of parasitemia and anemia, most mice infected with P yoelii 265 BY or 17X NL clone A recovered. For clone A, there were no differences on parasite load during recrudescence in mice treated and not treated with IFN-α. Treatment was stopped at day 25, and this caused a small augmentation of reticulocytes in blood circulation (data not shown). However, this augmentation in the number of reticulocytes was not sufficient to allow a significant increase in parasite development during recrudescence in treated animals as compared with untreated ones.

Here we demonstrated that IFN-α inhibits blood parasite load in mice infected with 2 different strains of P yoelii and that this phenomenon was associated with the inhibition of reticulocytosis. Our interpretation of the effect of IFN-α on blood parasite load is not necessarily applicable to all human parasites, since they show different tropism for reticulocytes. However, the merozoites of certain human malaria species, such as Plasmodium vivax, invade only reticulocytes. Reticulocytes and young RBCs are also more susceptible to invasion by certain strains of Plasmodium falciparum than are older RBCs. It has to be noted that virus infections, such as dengue virus or hepatitis B virus, are very frequent in most areas where malaria is endemic, and these virus infections trigger the production of high concentrations of IFN-α, even for long periods. This suggests that P vivax and P falciparum parasites may be susceptible to the effect of IFN-α. Thus, virus infections might influence the course and pathogenesis of malaria infection in virus-infected humans. Moreover, in people infected with more than one species or strain of Plasmodium, viral infection could lead to a selection of the parasite species or strain with tropism for mature cells. There have been few reports to date that suggest that IFN-α is produced during falciparum malaria infection. As mixed infections of P falciparum and P vivax are frequent in several malaria-endemic regions, it is tempting to speculate that in coinfected humans, IFN-α induced by P falciparum infection could block the production of reticulocytes.
and inhibit the development of *P. vivax*. This clearly deserves further study.

In conclusion, we propose that IFN-α inhibits *P. yoelii* infection by blocking reticulocyte production. We also have proposed that mice treated with rhIFN-α could be a good experimental model for studies on the way malaria infection causes anemia and regulates parasite interactions in coinfected individuals.

## Acknowledgments

We thank Dr E. Hulier for her help in quantification of parasite by PCR; Dr David Woodrow for histology; Dr Georges Snounou for carefully reviewing the manuscript; and Dr Owen Parkes for editing the English text.

## References


Inhibition of *Plasmodium yoelii* blood-stage malaria by interferon α through the inhibition of the production of its target cell, the reticulocyte

Ana Margarida Vigário, Elodie Belnoue, Ana Cumano, Myriam Marussig, François Miltgen, Irene Landau, Dominique Mazier, Ion Gresser and Laurent Rénia